They filed a Form 10. They're obligated to file 10qs and audited 10ks. Shouldn't be an issue with their new huge accounting firm.
Thanks for the information. I see two things happening here:
1. A reverse split to price them out of the penny stock world.
2. Financing from a large reputable firm that wouldn't touch a non-reporting company at penny stock prices.
I'd get particularly excited if a large reputable firm financed them at this price. Ultimate goal, assuming their unique and patented biotechnology is effective, is uplisting to NASDAQ. Investment from a large reputable firm at this price would imply to me that the firm thinks they might get over the $5 level on their own. That would be nice. I think though that the reverse split first is the most likely scenario.
My posts are my opinion. Do not be influenced by anything you read on any message board website unless you can confirm it.